BUPROPIONA E NALTREXONA COMO ESTRATÉGIA PARA CONTROLE DE PESO: UMA REVISÃO CRÍTICA DA LITERATURA

In the past three decades, obesity has emerged as one of the most concerning global epidemics, affecting millions of people and challenging healthcare systems worldwide. Characterized as a disease of caloric imbalance, obesity is associated with a range of serious complications, including cardiovascular diseases, type 2 diabetes, hypertension, and various forms of cancer, as well as significant psychological impacts. Given the complexity and multifactorial nature of obesity, integrated approaches that combine lifestyle changes with pharmacological interventions are often necessary to achieve sustainable weight loss and improve the overall health of patients. Among the medications used for weight loss, the combination of Bupropion and Naltrexone is notable. The aim of this study was to explore the action and effectiveness of the use of Bupropion Hydrochloride combined with Naltrexone Hydrochloride in the treatment and management of weight loss in obese patients. This is an integrative literature review on the importance of Bupropion in the pharmacological treatment of obesity. This search was conducted in the PUBMED database using the keywords: “Bupropion,” “Naltrexone,” and “Weight loss,” filtering only articles published in the last 10 years, conducted in humans, and with full-text availability. Lifestyle intervention and pharmacotherapy are important approaches to weight loss. In summary, all articles reviewed in their entirety demonstrated efficacy in treatment with Bupropion and Naltrexone. Moreover, they proved effectiveness in reducing metabolic risks in individuals with overweight and obesity.